BiomX (PHGE)

• Market cap: $13.5M
• 1 day: -0.11%
• 5 days: 2.04%
• 1 month: -11.52%
• 3 months: -29.65%
• 6 months: -43.18%
• Year to date: -31.25%
• 1 year: -80.73%
• 5 years: -98.92%
• 10 years: -99.44%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

Employees: 57

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

20% more funds holding

Funds holding: 15 [Q3] → 18 (+3) [Q4]

4.73% more ownership

Funds ownership: 50.59% [Q3] → 55.32% (+4.73%) [Q4]

21% less capital invested

Capital invested by funds: $9.24M [Q3] → $7.32M (-$1.92M) [Q4]

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $21 3,791% upside
• Avg. target: $21 3,791% upside
• High target: $21 3,791% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 62 / 415 met price target

3,791% upside $21

Buy Reiterated

4 Apr 2025